April 12, 2023

64B is a small molecule therapeutic that inhibits the function of hypoxia inducible factors (HIFs)

64B given systemically inhibits primary tumor growth and metastases

64B was far superior to either sunitinib or selumetinib at causing a regression in tumor size and in reducing the number and size of liver metastases

Atlanta, GA – April 12, 2023 – OncoSpherix, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors in variety of cancer indications, today announces a poster presentation at the upcoming American Association for Cancer Research (AACR) 2023 Annual Meeting being held in Orlando, FL, April 14-19, 2023. The presentation details are as follows:

Title: Hypoxia inducible factor (HIF) inhibitor 64B has superior anti-tumor effects compared to tow different tyrosine kinase inhibitors when tested in mouse models of uveal melanoma

Poster: 485/16

Authors: Yang, Grossniklaus, Van Meir, Offermann

Date / Time: April 16, 2023 / 1:30pm to 5:00pm

Location: Section 17

About OncoSpherix:

OncoSpherix, Inc., based in Atlanta, GA, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supplies, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candidate has been shown in mouse models to reduce primary tumor growth, inhibit metastasis, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). OncoSpherix intends to advance its lead candidate in one or more of these indications, in combination with agents that show therapeutic synergy while being well-tolerated as part of the combination.

Company Contact:

Allan Valmonte, MBA

Vice President, Business Operations

valmonte@oncospherix.com

Source: OncoSpherix, Inc.